

Everything you need to know about FLU 2018

References

1. Huang Q. Key findings - SHIVERS. 2016 New Zealand Influenza Symposium; Wellington, New Zealand; 2016.
2. Australasian Society of Clinical Immunology and Allergy. Vaccination of the egg-allergic individual. Sydney: Australasian Society of Clinical Immunology and Allergy; 2017.
3. Medsafe. Data sheet – Influvac Tetra [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2017 [updated 2017 December 19; cited 2018 January 19]. Available from: <http://www.medsafe.govt.nz/profs/Datasheet/i/InfluvacTetrainj.pdf>.
4. Therapeutic Goods Administration. Fluarix Tetra product information [Internet]. Australian Capital Territory: Therapeutic Goods Administration; 2013 [updated 2017 November 9]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-02216-1>.
5. Bresee J, Fry A, Suryaprakash S, Cos N. Inactivated influenza vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2017. p. 456-88.
6. Centers for Disease Control and Prevention. Influenza (Flu): Influenza signs and symptoms and the role of laboratory diagnostics [Internet]. Atlanta: Centers for Disease Control and Prevention; 2016 [updated 2016 October 26; cited 2017 November 17]. Available from: <https://www.cdc.gov/flu/professionals/diagnosis/labrolesprocedures.htm>.
7. Ministry of Health. Communicable disease control manual 2012 (last updated December 2017). Wellington: Ministry of Health; 2012.
8. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: A review of volunteer challenge studies. *Am J Epidemiol*. 2008;167(7):775-85.
9. Huang Y, Zaas AK, Rao A, Dobbigeon N, Woolf PJ, Veldman T, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. *PLOS Genetics*. 2011;7(8):e1002234.
10. Jutel A, Baker MG, Stanley J, Huang QS, Bandaranayake D. Self-diagnosis of influenza during a pandemic: A cross-sectional survey. *BMJ Open*. 2011;1(2):e000234.
11. Institute of Environmental Science and Research Ltd (ESR). Recommendation for seasonal influenza vaccine composition for New Zealand 2018. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2017.
12. World Health Organization. Vaccines against influenza WHO position paper – November 2012. *Wkly Epidemiol Rec*. 2012;47(87):461-76.
13. Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: Systematic review and grading of evidence. *Clin Infect Dis*. 2014;58(1):50-7.
14. Dolan GP, Harris RC, Clarkson M, Sokal R, Morgan G, Mukaigawara M, et al. Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: Summary of a systematic review. *Influenza Other Respir Viruses*. 2013;7(S2):93-6.
15. Riphagen-Dalhuisen J, Burgerhof J, Frijstein G, van der Geest-Blankert A, Danhof-Pont M, de Jager H, et al. Hospital-based cluster randomised controlled trial to assess effects of a multi-faceted programme on influenza vaccine coverage among hospital healthcare workers and nosocomial influenza in the Netherlands, 2009 to 2011. *Euro Surveill*. 2013;18(26):pii=20512.
16. Ministry of Health. 2017 Workforce influenza immunisation coverage rates by District Health Boards [Internet]. Wellington: Ministry of Health; 2017 [cited 2017 December 19]. Available from: <https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/influenza>.
17. Kunzel W, Engelmann H, D'Hondt E. Immune response to influenza vaccination. *Lancet*. 1994;343(8890):173.
18. Zuckerman M, Cox RJ, Taylor J, Wood JG, Haaheim L, Oxford J. Rapid immune response to influenza vaccination. *Lancet*. 1993;342(8879):113.
19. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season. Internet. Geneva: World Health Organization; 2017.
20. Ministry of Health. Health and Disability Services Eligibility Direction 2011 [Internet]. Wellington: Ministry of Health; 2011 [cited 2017 December 28]. Available from: <https://www.health.govt.nz/new-zealand-health-system/eligibility-publicly-funded-health-services/eligibility-direction>.
21. Ministry of Health. Section 88 Primary Maternity Services Notice 2007 [Internet]. Wellington: Ministry of Health; 2007 [updated 2017 July 31; cited 2017 December 28]. Available from: <https://www.health.govt.nz/publication/section-88-primary-maternity-services-notice-2007>.
22. Pharmaceutical Management Agency (PHARMAC). Pharmaceutical schedule [Internet]. Wellington: PHARMAC; March 2018 [cited 2018 February 26]. Available from: <http://www.pharmac.govt.nz/2018/03/01/Schedule.pdf>.
23. Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. *J Clin Pharm Ther*. 2012;37(5):505-9.
24. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. *JAMA Pediatrics*. 2014;168(3):211-9.
25. Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. *Vaccine*. 2011;29(32):5195-202.
26. Socan M, Frelj T, Janet E, Petraš T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. *Vaccine*. 2004;22(23-24):3087-91.
27. Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial. *Vaccine*. 2017;35(46):6321-8.
28. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. *Clinical and experimental vaccine research*. 2017;6(1):38-44.
29. Australasian Society of Clinical Immunology and Allergy. Sulfite sensitivity. Sydney: Australasian Society of Clinical Immunology and Allergy Inc.; 2014.
30. Medsafe. Data sheet – Fluarix Tetra [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2017 [updated 2017; cited 2018].

Everything you need to know about FLU 2018

31. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer Ghada A, Al-Ansary Lubna A, Ferroni E. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev.* 2010(7):Art. No.: CD001269.
32. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. *Lancet Infect Dis.* 2012;12(1):36-44.
33. Beyer WEP, Nauta JJP, Palache AM, Giezenman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. *Vaccine.* 2011;29(34):5785-92.
34. van de Witte SV, Nauta J, Giezenman-Smits KM, de Voogd JM. Trivalent inactivated subunit influenza vaccine Influvac: 30-year experience of safety and immunogenicity. *Trials Vaccinol.* 2012;1:42-8.
35. Zuccotti GV, Fabiano V. Influvac, a trivalent inactivated subunit influenza vaccine. *Expert Opin Biol Ther.* 2011;11(1):89-98.
36. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged ≥ 18 years. *BMC Infect Dis.* 2013;13:343.
37. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. *Vaccine.* 2013;31(5):770-6.
38. Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. *Vaccine.* 2015;33(46):6149-51.
39. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. *Vaccine.* 2016;34(35):4092-102.
40. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. *Vaccine.* 2012;30(33):4945-52.
41. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. *Pediatr Infect Dis J.* 2014;33(6):630-6.
42. Rodriguez Weber MA, Claeys C, Doniz CA, Feng Y, Innis BL, Jain VK, et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. *Pediatr Infect Dis J.* 2014;33(12):1262-9.
43. Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: A randomized, double-blind, controlled, multicenter, multicountry, clinical trial. *J Pediatric Infect Dis Soc.* 2015;4(3):242-51.
44. Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6-35 months of age during 2013-2014: Results from a phase II randomized trial. *J Pediatric Infect Dis Soc.* 2016;5(2):170-9.
45. Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O, Rodríguez-Weber MA, Leonardi ML, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a phase III, randomized, controlled trial. *J Pediatr Infect Dis Soc.* 2017;6(1):9-19.
46. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol.* 2016;137(3):868-78.
47. Hughes RAC, Cornblath DR. Guillain-Barre syndrome. *Lancet.* 2005;366(9497):1653-66.
48. Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, Ziegler D, Retalliau H, et al. Guillain-Barre syndrome following vaccination in the National Influenza Program, United States, 1976-1977. *Am J Epidemiol.* 1979;110(2):105-23.
49. Arias LHM, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. *Vaccine.* 2015;33(31):3773-8.
50. Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barre syndrome, influenza-related hospitalizations, and influenza vaccine coverage. *Vaccine.* 2015;33(17):2045-9.
51. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. *Am J Epidemiol.* 2009;169(3):382-8.
52. Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barre syndrome: Making informed decisions. *Lancet.* 2013;381(9876):1437-9.
53. Sadleir LG, Scheffer IE. Febrile seizures. *BMJ.* 2007;334(7588):307-11.
54. Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. *Hum Vaccin Immunother.* 2017;13(7):1640-52.
55. Jefferson T, Di Pietrantonj C, Al-Ansary Lubna A, Ferroni E, Thorning S, Thomas Roger E. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev.* 2010(2):Art. No.: CD004876.
56. Beyer WEP, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus ADME. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. *Vaccine.* 2013;31(50):6030-3.
57. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. *Arch Pediatr Adolesc Med.* 2011;165(2):104-11.
58. Poehling K, Szilagyi P, Staat M, Snively B, Payne D, Bridges C, et al. Impact of maternal immunization on influenza hospitalizations in infants. *Am J Obstet Gynecol.* 2011;204(Suppl 6):S141-8.
59. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med.* 2014;371(10):918-31.
60. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev.* 2012(8):Art. No.: CD004879.
61. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: An observational cohort study. *Lancet Infect Dis.* 2011;11(1):23-9.
62. Blythe C, Macartney K, Hewagama S, Senenayake S, Friedman N, Simpson G, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014: The Influenza Complications Alert Network (FluCAN). *Euro Surveill.* 2016;21(30):30301.
63. Turner N, Pierse N, Bissielo A, Huang QS, Radke S, Baker M, et al. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. *Euro Surveill.* 2014;19(34):20884.
64. Regan AK, de Klerk N, Moore HC, Omer SB, Shellam G, Effler PV. Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: A retrospective cohort study. *Vaccine.* 2016;34(32):3649-56.
65. Turner N, Pierse N, Bissielo A, QS H, Baker M, Widdowson M-A, et al. The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. *Vaccine.* 2014;32(29):3687-93.

Everything you need to know about FLU 2018

66. Pierse N, Kelly H, Thompson MG, Bissielo A, Radke S, Huang QS, et al. Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014. *Vaccine*. 2016;34(4):503-9.
67. Bissielo A, Pierse N, Huang Q, Thompson M, Kelly H, Mishin V, et al. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: Interim estimates. *Euro Surveill*. 2016;21(1):30101.
68. Institute of Environmental Science and Research Ltd (ESR). Recommendation for seasonal influenza vaccine composition for New Zealand 2017. Wellington: Institute of Environmental Science and Research Ltd; 2016. Report No.: FW16045.
69. Loubet P, Loulergue P, Galtier F, Launay O. Seasonal influenza vaccination of high-risk adults. *Expert Rev Vaccines*. 2016;15(12):1507-18.
70. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: Systematic review and meta-analysis. *BMJ*. 2013;347:f5061.
71. Chan TC, Fan-Ngai Hung I, Ka-Hay Luk J, Chu LW, Hon-Wai Chan F. Effectiveness of influenza vaccination in institutionalized older adults: A systematic review. *Journal of the American Medical Directors Association*. 2014;15(3):226 e1-6.
72. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: A meta-analysis of test-negative design case-control studies. *Lancet Infect Dis*. 2014;14(12):1228-39.
73. Mosnier A, Daviaud I, Caini S, Berche H, Mansuy J-M, van der Werf S, et al. Does seasonal vaccination affect the clinical presentation of influenza among the elderly? A cross-sectional analysis in the outpatient setting in France, 2003–2014. *Vaccine*. 2017;35(16):2076-83.
74. Harris J. Influenza occurring in pregnant women: A statistical study of thirteen hundred and fifty cases. *JAMA*. 1919;72(14):978-80.
75. Dodds L, McNeill S, Fell D, Allen V, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *CMAJ*. 2007;176(4):463-8.
76. Dreier JW, Andersen A-MN, Berg-Beckhoff G. Systematic review and meta-analyses: Fever in pregnancy and health impacts in the offspring. *Pediatrics*. 2014;133(3):e674-88.
77. Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, et al. Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy. *Proc Natl Acad Sci U S A*. 2014;111(40):14506-11.
78. Mosby L, Rasmussen S, Jamieson D. 2009 pandemic influenza A (H1N1) in pregnancy: A systematic review of the literature. *Am J Obstet Gynecol*. 2011;205(1):10-8.
79. Omer SB, Bednarczyk RA, Madhi SA, Klugman KP. Benefits to mother and child of influenza vaccination during pregnancy. *Hum Vaccin Immunother*. 2012;8(1):130-7.
80. Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, et al. The burden of influenza in young children, 2004–2009. *Pediatrics*. 2013;131(2):207-16.
81. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. *Eur J Pediatr*. 2014;173(3):265-76.
82. van Kerkhove MD, Vandemaële KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: A global pooled analysis. *PLoS Med*. 2011;8(7):e1001053.
83. Marshall H, McMillan M, Andrews RM, Macartney K, Edwards K. Vaccines in pregnancy: The dual benefit for pregnant women and infants. *Hum Vaccin Immunother*. 2016;12(4):848-56.
84. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. *Clin Infect Dis*. 2010;51(12):1355-61.
85. Jamieson DJ, Kissin DM, Bridges CB, Rasmussen SA. Benefits of influenza vaccination during pregnancy for pregnant women. *Am J Obstet Gynecol*. 2012;207(Suppl 3):S17-20.
86. Nunes MC, Cutland CL, Jones S, et al. Duration of infant protection against influenza illness conferred by maternal immunization: Secondary analysis of a randomized clinical trial. *JAMA Pediatrics*. 2016;170(9):840-7.
87. Shakib JH, Korgenski K, Presson AP, Sheng X, Varner MW, Pavia AT, et al. Influenza in infants born to women vaccinated during pregnancy. *Pediatrics*. 2016;137(6):e20152360.
88. van Santen KL, Bednarczyk RA, Adjaye-Gbewonyo D, Orenstein WA, Davis R, Omer SB. Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. *Pediatr Infect Dis J*. 2013;32(11):1180-4.
89. Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. *Am J Obstet Gynecol*. 2012;207(Suppl 3):S38-46.
90. Global Advisory Committee on Vaccine Safety. Safety of immunization during pregnancy: A review of the evidence. Internet. Geneva: World Health Organization; 2014.
91. Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway A, Lee G, Nordin JD, et al. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstet Gynecol*. 2013;122(3):659-67.
92. Nordin JD, Kharbanda EO, Benitez GV, Nichol K, Lipkind H, Naleway A, et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. *Obstet Gynecol*. 2013;121(3):519-25.
93. Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal influenza vaccination and risk for congenital malformations: A systematic review and meta-analysis. *Obstet Gynecol*. 2015;126(5):1075-84.
94. Regan AK, Moore HC, de Klerk N, Omer SB, Shellam G, Mak DB, et al. Seasonal trivalent influenza vaccination during pregnancy and the incidence of stillbirth: Population-based retrospective cohort study. *Clin Infect Dis*. 2016;62(10):1221-7.
95. Sheffield JS, Greer LG, Rogers VL, Roberts SW, Lytle H, McIntire DD, et al. Effect of influenza vaccination in the first trimester of pregnancy. *Obstet Gynecol*. 2012;120(3):532-7.
96. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: A systematic review and meta-analysis. *Clin Infect Dis*. 2015;60(5):e11-9.
97. Chambers CD, Johnson DL, Xu R, Luo YJ, Louik C, Mitchell AA, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. *Vaccine*. 2016;34(37):4443-9.
98. McHugh L, Andrews RM, Lambert SB, Viney KA, Wood N, Perrett KP, et al. Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012–2014: The FluMum study. *Vaccine*. 2017;35(10):1403-9.
99. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: A systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. *Vaccine*. 2015;33(18):2108-17.
100. Zerbo O, Modaresi S, Chan B, Goddard K, Lewis N, Bok K, et al. No association between influenza vaccination during pregnancy and adverse birth outcomes. *Vaccine*. 2017;35(24):3186-90.
101. Zhang C, Wang X, Liu D, Zhang L, Sun X. A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy. *Int J Gynaecol Obstet*. Forthcoming 2017.

Everything you need to know about FLU 2018

102. Litmus Limited. Immunisation for pregnant women: Audience research with pregnant women. Wellington: Ministry of Health; 2015.
103. Henninger ML, Irving SA, Thompson M, Avalos LA, Ball SW, Shifflett P, et al. Factors associated with seasonal influenza vaccination in pregnant women. *J Womens Health*. 2015;24(5):394-402.
104. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: A literature review. *Vaccine*. 2015;33(47):6420-9.
105. Yuen CYS, Tarrant M. Determinants of uptake of influenza vaccination among pregnant women – A systematic review. *Vaccine*. 2014;32(36):4602-13.
106. Meharry PM, Colson ER, Grizas AP, Stiller R, Vázquez M. Reasons why women accept or reject the trivalent inactivated influenza vaccine (TIV) during pregnancy. *Matern Child Health J*. 2013;17(1):156-64.
107. Branch DW. Physiologic adaptations of pregnancy. *Am J Reprod Immunol*. 1992;28(3-4):120-2.
108. Jamieson D, Theiler R, Rasmussen S. Emerging infections and pregnancy. *Emerg Infect Dis*. 2006;12(11):1638-43.
109. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. *Horm Behav*. 2012;62(3):263-71.
110. Bithell JF, Draper GJ, Gorbach PD. Association between malignant disease in children and maternal virus infections. *Br Med J*. 1973;1(5855):706.
111. Bennet R, Hamrin J, Wirtgart BZ, Ostlund MR, Ortqvist A, Eriksson M. Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998–2014. *Vaccine*. 2016;34(28):3298-302.
112. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. *Obstet Gynecol*. 2012;119(3):631-9.
113. Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Altaye M, et al. Influenza immunization in pregnancy – Antibody responses in mothers and infants. *N Engl J Med*. 2010;362(17):1644-6.
114. The American College of Obstetricians and Gynecologists. Influenza vaccination during pregnancy [Internet]. The American Congress of Obstetricians and Gynecologists; 2014 [updated 2016; cited 2017 December 29]. Available from: <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Influenza-Vaccination-During-Pregnancy>.
115. Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. *Vaccine*. 2017;35(40):5314-22.
116. Chambers CD, Xu R, Mitchell AA. Commentary on: “Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12”. *Vaccine*. 2017;35(40):5323-4.
117. The American Congress of Obstetricians and Gynecologists. Practice advisory: Influenza vaccination during pregnancy [Internet]. The American Congress of Obstetricians and Gynecologists; 2017 [cited 2017 December 29]. Available from: <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Influenza-Vaccination-During-Pregnancy>.
118. Buchan SA, Hottes TS, Rosella LC, Crowcroft NS, Tran D, Kwong JC. Contribution of influenza viruses to medically attended acute respiratory illnesses in children in high-income countries: A meta-analysis. *Influenza Other Respir Viruses*. 2016;10(6):444-54.
119. Heikkinen T, Silvennoinen H, Heinonen S, Vuorinen T. Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children. *Eur J Clin Microbiol Infect Dis*. 2016;35(7):1107-13.
120. Grohskopf L, Sokolow L, Broder K, Walter E, Bresee J, Fry A, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 influenza season. *MMWR Recomm Rep*. 2017;66(2):1-20.
121. Public Health England. National flu immunisation programme plan for 2017 to 2018. London: Public Health England; 2017.
122. Gill PJ, Ashdown HF, Wang K, Heneghan C, Roberts NW, Harnden A, et al. Identification of children at risk of influenza-related complications in primary and ambulatory care: A systematic review and meta-analysis. *Lancet Respir Med*. 2015;3(2):139-49.
123. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naïve 5–8-year-old children. *J Infect Dis*. 2006;194(8):1032-9.
124. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: Two open-label, randomised controlled trials. *Lancet*. 2009;374:1339-50.
125. Pollyea DA, Brown JMY, Horning SJ. Utility of influenza vaccination for oncology patients. *J Clin Oncol*. 2010;28(14):2481-90.
126. Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. *J Infect Dis*. 2012;206(8):1250-9.
127. Askling HH, Rombo L. Influenza in travellers. *Curr Opin Infect Dis*. 2010;23(5):421-5.
128. Steffen R. Influenza in travelers: Epidemiology, risk, prevention, and control issues. *Curr Infect Dis Rep*. 2010;12(3):181-5.
129. Browne A, St-Onge Ahmad S, Beck CR, Nguyen-Van-Tam JS. The roles of transportation and transportation hubs in the propagation of influenza and coronaviruses: A systematic review. *J Travel Med*. 2016;23(1).
130. Brotherton JML, Delpech VC, Gilbert GL, Hatzi S, Paraskevopoulos PD, McAnulty JM. A large outbreak of influenza A and B on a cruise ship causing widespread morbidity. *Epidemiol Infect*. 2003;130(2):263-71.
131. Miller JM, Tam TWS, Maloney S, Fukuda K, Cox N, Hockin J, et al. Cruise ships: High-risk passengers and the global spread of new influenza viruses. *Clin Infect Dis*. 2000;31(2):433-8.
132. Gautret P, Soula G, Parola P, Brouqui P. Hajj pilgrims' knowledge about acute respiratory infections. *Emerg Infect Dis*. 2009;15(11):1861.
133. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Internet. Geneva: World Health Organization; 2017.